United States

Janssen Pharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

World Dairy Expo

Participation Not Confirmed

Update your events

Health Canada Approves Janssen Pharmaceutical's TREMFYA®, a First-In-Class Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Art...

Lead Product(s): Guselkumab

Therapeutic Area: Immunology Product Name: Tremfya

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 10, 2020

Details:

TREMFYA® is the first and only biologic approved for the treatment of both active PsA and moderate to severe plaque psoriasis that selectively inhibits interleukin (IL)-23, a naturally occurring cytokine involved in normal inflammatory and immune responses.

Viela Bio

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

World Dairy Expo

Participation Not Confirmed

Update your events

Viela Bio Announces Data Presentations at the 8Th Joint Actrims-Ectrims Meeting, Ms Virtual 2020

Lead Product(s): Inebilizumab

Therapeutic Area: Immunology Product Name: Uplizna

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 03, 2020

Details:

First poster will highlights study results in AQP4-IgG seronegative patients in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder.

Aimmune Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

World Dairy Expo

Participation Not Confirmed

Update your events

Nestlé to Acquire Aimmune Therapeutics

Lead Product(s): Peanut Allergen Powder-dnfp

Therapeutic Area: Immunology Product Name: Palforzia

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Nestle Health Sciences SA

Deal Size: $1,930.0 million Upfront Cash: $1,930.0 million

Deal Type: Acquisition August 31, 2020

Details:

Aimmune's recently approved therapy Palforzia® would expand Nestlé Health Science portfolio with first and only FDA-approved treatment to help reduce the frequency and severity of allergic reactions to peanuts in children.

EyePoint Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

World Dairy Expo

Participation Not Confirmed

Update your events

EyePoint Pharmaceuticals Secures New Purchase and Marketing Agreement with Vantage Outsourcing for DEXYCU®

Lead Product(s): Dexamethasone

Therapeutic Area: Immunology Product Name: Dexycu

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Vantage Outsourcing

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement August 24, 2020

Details:

The agreement will enable customers in the Vantage Outsourcing network, which spans over a 25+ state service area, to incorporate DEXYCU into their surgical protocols for treating ocular inflammation associated with cataract surgery.

KALEO INC

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

World Dairy Expo

Participation Not Confirmed

Update your events

Kaléo and the Pan-Canadian Pharmaceutical Alliance (pCPA) Complete Negotiations for ALLERJECT® Auto-Injector

Lead Product(s): Adrenaline

Therapeutic Area: Immunology Product Name: Allerject

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: pan Canadian Pharmaceutical Alliance

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement August 10, 2020

Details:

Kaléo has completed negotiations with the pan Canadian Pharmaceutical Alliance (pCPA) for a Letter of Intent regarding ALLERJECT® (epinephrine injection, USP) auto-injector for the treatment of serious allergic reactions.

EyePoint Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

World Dairy Expo

Participation Not Confirmed

Update your events

EyePoint Pharmaceuticals and ImprimisRx Announce U.S. Commercial Alliance for Dexycu

Lead Product(s): Dexamethasone

Therapeutic Area: Immunology Product Name: Dexycu

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: EyePoint Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration August 04, 2020

Details:

Under the terms of the commercial alliance, ImprimisRx will deploy its sales specialists and their inside sales team to promote DEXYCU to ophthalmologist, hospital, and ambulatory surgical center (ASC) customers beginning immediately.

Janssen Pharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

World Dairy Expo

Participation Not Confirmed

Update your events

TREMFYA® Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis

Lead Product(s): Guselkumab

Therapeutic Area: Immunology Product Name: Tremfya

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 14, 2020

Details:

In two Phase 3 clinical trials, TREMFYA significantly improved signs and symptoms in joints, skin and soft tissue in adults with active psoriatic arthritis.

AbbVie Inc

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

World Dairy Expo

Participation Not Confirmed

Update your events

AbbVie's RINVOQ Meets Primary and Key Secondary Endpoints in Phase 3 Head-to-Head Study Versus ORENCIA in RA Patients

Lead Product(s): Upadacitinib

Therapeutic Area: Immunology Product Name: Rinvoq

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 06, 2020

Details:

In SELECT-CHOICE, RINVOQ™ (upadacitinib) met both the primary and key secondary endpoints compared to ORENCIA® (abatacept) on change from baseline in DAS28-CRP at week 12 in patients with rheumatoid arthritis and inadequate response to biologic DMARDs.

AbbVie Inc

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

World Dairy Expo

Participation Not Confirmed

Update your events

New Long-Term Data from RINVOQ Phase 3 Studies in Rheumatoid Arthritis

Lead Product(s): Upadacitinib,Methotrexate

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 04, 2020

Details:

Long-term results from the SELECT-COMPARE and SELECT MONOTHERAPY studies showed that RINVOQ™ (upadacitinib, 15 mg) continued to improve signs and symptoms in patients with rheumatoid arthritis through 72 and 84 weeks, respectively.

Eli Lilly

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

World Dairy Expo

Participation Not Confirmed

Update your events

Lilly's Taltz Outpaces Novartis' Cosentyx with 4th FDA Approval

Lead Product(s): Ixekizumab

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 01, 2020

Details:

This approval is based on the results from the Phase 3 COAST-X trial, which evaluated improvement in signs and symptoms of nr-axSpA as measured by the proportion of patients who achieved ASAS40 response criteria compared to placebo.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Janssen Pharmaceutical

Health Canada Approves Janssen Pharmaceutical's TREMFYA®, a First-In-Class Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Art...

Viela Bio

Viela Bio Announces Data Presentations at the 8Th Joint Actrims-Ectrims Meeting, Ms Virtual 2020

Aimmune Therapeutics

Nestlé to Acquire Aimmune Therapeutics

EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Secures New Purchase and Marketing Agreement with Vantage Outsourcing for DEXYCU®

KALEO INC

Kaléo and the Pan-Canadian Pharmaceutical Alliance (pCPA) Complete Negotiations for ALLERJECT® Auto-Injector

EyePoint Pharmaceuticals

EyePoint Pharmaceuticals and ImprimisRx Announce U.S. Commercial Alliance for Dexycu

Janssen Pharmaceutical

TREMFYA® Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis

AbbVie Inc

AbbVie's RINVOQ Meets Primary and Key Secondary Endpoints in Phase 3 Head-to-Head Study Versus ORENCIA in RA Patients

AbbVie Inc

New Long-Term Data from RINVOQ Phase 3 Studies in Rheumatoid Arthritis

Eli Lilly

Lilly's Taltz Outpaces Novartis' Cosentyx with 4th FDA Approval